Fungal eyelid treatment study
This study tests an antifungal eye drop called Natacyn for blepharitis, an eyelid inflammation that may be caused by fungus. Participants use the drops four times a day for three weeks to see if it clears the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with blepharitis (eyelid inflammation or flaking).
- Your eyelid infection has been confirmed as fungal by a lab test.
- You can commit to using the eye drops four times a day for 21 days.
- If you are a woman who can have children, you must agree to use birth control during the study and for 30 days after.
- You have not used antifungal medication in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria on the eyelids of people with moderate to severe eyelid inflammation (blepharitis). It aims to understand if these bacteria are linked to the condition, which could lead to better treatments.
This study tests an investigational new eye drop called IVIEW-1201 for treating fungal keratitis, a fungal infection of the cornea. It aims to see if it is safe and effective compared to standard treatment, which could help clear the infection and protect your vision.
This trial tests if adding cyclosporine A to the standard natamycin eye drops can better treat fungal eye infections. It may help people with moderate vision loss from a fungal corneal infection.
This trial tests an investigational eye drop (GLK-321) to see if it safely and effectively treats Demodex blepharitis, an eyelid inflammation caused by tiny mites. It may help people who have signs of this condition and good enough vision.
This trial tests a new eye drop (acoltrepon) to see if it helps people with stage 1 neurotrophic keratopathy (a condition where the cornea's nerves are damaged, causing dry eyes and vision problems) and low tear production. It aims to improve signs like corneal staining and symptoms of discomfort.
This Phase 2 study tests whether eye drops containing a medicine called N-acetylcysteine (NAC) can reduce damaging “reactive oxygen” in people with advanced Fuchs’ endothelial corneal dystrophy (FECD). It involves people who need a special cornea transplant (DMEK) at the same time as cataract surgery, aiming to improve cornea healing and vision.
Hear when a new Anterior Blepharitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.